Opinion|Videos|October 19, 2026
Safety and Monitoring – Hypophosphatemia, Infusion Reactions, and Adverse-Event Management
Justin Arnall, Breanna Taylor, and Jeff Goff weigh in on hypophosphatemia risk across IV iron formulations, strategies for managing infusion reactions, and whether generic versus branded products affect reaction rates in practice.
Advertisement
Justin Arnall, Breanna Taylor, and Jeff Goff weigh in on hypophosphatemia risk across IV iron formulations, strategies for managing infusion reactions, and whether generic versus branded products affect reaction rates in practice.
Advertisement
Related to this article
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Finerenone in Heart Failure: Evidence and Practice a Year Later
3
Pelacarsen, Ziltivekimab Miss CV End Points: What to Know
4
Breast Cancer Treatment Ends, But The Medication Questions Don’t
5